These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1949134)

  • 1. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria.
    Sherwood JA; Oster CN; Adoyo-Adoyo M; Beier JC; Gachihi GS; Nyakundi PM; Ballou WR; Brandling-Bennett AD; Schwartz IK; Were JB
    Trans R Soc Trop Med Hyg; 1991; 85(3):336-40. PubMed ID: 1949134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
    Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
    Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum.
    Hoffman SL; Wistar R; Ballou WR; Hollingdale MR; Wirtz RA; Schneider I; Marwoto HA; Hockmeyer WT
    N Engl J Med; 1986 Sep; 315(10):601-6. PubMed ID: 3526148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sporozoite malaria vaccine. Where do we stand?
    Nussenzweig V; Nussenzweig S
    Ann Parasitol Hum Comp; 1990; 65 Suppl 1():49-52. PubMed ID: 1702271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites.
    Egan JE; Hoffman SL; Haynes JD; Sadoff JC; Schneider I; Grau GE; Hollingdale MR; Ballou WR; Gordon DM
    Am J Trop Med Hyg; 1993 Aug; 49(2):166-73. PubMed ID: 8357078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.
    Sherwood JA; Copeland RS; Taylor KA; Abok K; Oloo AJ; Were JB; Strickland GT; Gordon DM; Ballou WR; Bales JD; Wirtz RA; Wittes J; Gross M; Que JU; Cryz SJ; Oster CN; Roberts CR; Sadoff JC
    Vaccine; 1996 Jun; 14(8):817-27. PubMed ID: 8817830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antibody responses to the circumsporozoite protein repeat region and to intact sporozoites during acute falciparum malaria.
    Brown AE; Webster HK; Pavanand K; Permpanich B; Sookto P; Sattabongkot J; Gingrich JB
    Trans R Soc Trop Med Hyg; 1989; 83(2):154-7. PubMed ID: 2692219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of human volunteer sera to candidate Plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes.
    Hollingdale MR; Appiah A; Leland P; do Rosario VE; Mazier D; Pied S; Herrington DA; Chulay JD; Ballou WR; Derks T
    Trans R Soc Trop Med Hyg; 1990; 84(3):325-9. PubMed ID: 2175464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A.
    Fries LF; Gordon DM; Schneider I; Beier JC; Long GW; Gross M; Que JU; Cryz SJ; Sadoff JC
    Infect Immun; 1992 May; 60(5):1834-9. PubMed ID: 1563771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells.
    Herrington DA; Losonsky GA; Smith G; Volvovitz F; Cochran M; Jackson K; Hoffman SL; Gordon DM; Levine MM; Edelman R
    Vaccine; 1992; 10(12):841-6. PubMed ID: 1455910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmodium falciparum: sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine.
    Hoffman SL; Cannon LT; Berzofsky JA; Majarian WR; Young JF; Maloy WL; Hockmeyer WT
    Exp Parasitol; 1987 Aug; 64(1):64-70. PubMed ID: 2440712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of immunity in natural Plasmodium falciparum malaria: antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32).
    Webster HK; Boudreau EF; Pang LW; Permpanich B; Sookto P; Wirtz RA
    J Clin Microbiol; 1987 Jun; 25(6):1002-8. PubMed ID: 2439533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.
    Ballou WR; Hoffman SL; Sherwood JA; Hollingdale MR; Neva FA; Hockmeyer WT; Gordon DM; Schneider I; Wirtz RA; Young JF
    Lancet; 1987 Jun; 1(8545):1277-81. PubMed ID: 2884410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major population differences in T cell response to a malaria sporozoite vaccine candidate.
    Zevering Y; Houghten RA; Frazer IH; Good MF
    Int Immunol; 1990; 2(10):945-55. PubMed ID: 1706620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.
    Brown AE; Singharaj P; Webster HK; Pipithkul J; Gordon DM; Boslego JW; Krinchai K; Su-archawaratana P; Wongsrichanalai C; Ballou WR
    Vaccine; 1994 Feb; 12(2):102-8. PubMed ID: 8147091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human response to a malaria vaccine candidate antigen.
    Biswas S; Sharma YD
    Vaccine; 1991 Jul; 9(7):467-9. PubMed ID: 1897303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas.
    Ferreira-da-Cruz MF; Deslandes DC; Oliveira-Ferreira J; Montenegro-James S; Tartar A; Druilhe P; Daniel-Ribeiro CT
    Parasite; 1995 Mar; 2(1):23-9. PubMed ID: 9137641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent occurrence of protective anti-Plasmodium falciparum sporozoite antibodies in a holoendemic area of Liberia.
    Hollingdale MR; Hogh B; Petersen E; Wirtz RA; Bjorkmann A
    Trans R Soc Trop Med Hyg; 1989; 83(3):322-4. PubMed ID: 2694466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum.
    Etlinger HM; Felix AM; Gillessen D; Heimer EP; Just M; Pink JR; Sinigaglia F; Stürchler D; Takacs B; Trzeciak A
    J Immunol; 1988 Jan; 140(2):626-33. PubMed ID: 3275719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.
    Thompson FM; Porter DW; Okitsu SL; Westerfeld N; Vogel D; Todryk S; Poulton I; Correa S; Hutchings C; Berthoud T; Dunachie S; Andrews L; Williams JL; Sinden R; Gilbert SC; Pluschke G; Zurbriggen R; Hill AV
    PLoS One; 2008 Jan; 3(1):e1493. PubMed ID: 18231580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.